Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

N-myc proto-oncogene protein (Class E basic helix-loop-helix protein 37) (bHLHe37)

 MYCN_HUMAN              Reviewed;         464 AA.
P04198; Q53XS5; Q6LDT9;
20-MAR-1987, integrated into UniProtKB/Swiss-Prot.
01-JUL-1989, sequence version 2.
25-OCT-2017, entry version 192.
RecName: Full=N-myc proto-oncogene protein;
AltName: Full=Class E basic helix-loop-helix protein 37;
Short=bHLHe37;
Name=MYCN; Synonyms=BHLHE37, NMYC;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=2869488; DOI=10.1073/pnas.83.6.1772;
Stanton L.W., Schwab M., Bishop J.M.;
"Nucleotide sequence of the human N-myc gene.";
Proc. Natl. Acad. Sci. U.S.A. 83:1772-1776(1986).
[2]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=3510398; DOI=10.1038/319073a0;
Kohl N.E., Legouy E., DePinho R.A., Nisen P.D., Smith R.K., Gee C.E.,
Alt F.W.;
"Human N-myc is closely related in organization and nucleotide
sequence to c-myc.";
Nature 319:73-77(1986).
[3]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
PubMed=2834684;
Ibson J.M., Rabbitts P.H.;
"Sequence of a germ-line N-myc gene and amplification as a mechanism
of activation.";
Oncogene 2:399-402(1988).
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
Phelan M., Farmer A.;
"Cloning of human full-length CDSs in BD Creator(TM) system donor
vector.";
Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=15815621; DOI=10.1038/nature03466;
Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
Waterston R.H., Wilson R.K.;
"Generation and annotation of the DNA sequences of human chromosomes 2
and 4.";
Nature 434:724-731(2005).
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
Venter J.C.;
Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=Brain;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[8]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-40.
PubMed=3437890; DOI=10.1128/MCB.7.12.4266;
Stanton L.W., Bishop J.M.;
"Alternative processing of RNA transcribed from NMYC.";
Mol. Cell. Biol. 7:4266-4272(1987).
[9]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 71-464.
PubMed=3008339; DOI=10.1126/science.3008339;
Slamon D.J., Boone T.C., Seeger R.C., Keith D.E., Chazin V., Lee H.C.,
Souza L.M.;
"Identification and characterization of the protein encoded by the
human N-myc oncogene.";
Science 232:768-772(1986).
[10]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 313-464.
PubMed=2987858; DOI=10.1093/nar/13.7.2545;
Michitsch R.W., Melera P.W.;
"Nucleotide sequence of the 3' exon of the human N-myc gene.";
Nucleic Acids Res. 13:2545-2558(1985).
[11]
PHOSPHORYLATION AT SER-261 AND SER-263 BY CK2.
PubMed=1425701; DOI=10.1111/j.1432-1033.1992.tb17367.x;
Hagiwara T., Nakaya K., Nakamura Y., Nakajima H., Nishimura S.,
Taya Y.;
"Specific phosphorylation of the acidic central region of the N-myc
protein by casein kinase II.";
Eur. J. Biochem. 209:945-950(1992).
[12]
INTERACTION WITH KDM5A AND KDM5B.
PubMed=17311883; DOI=10.1101/gad.1523007;
Secombe J., Li L., Carlos L., Eisenman R.N.;
"The Trithorax group protein Lid is a trimethyl histone H3K4
demethylase required for dMyc-induced cell growth.";
Genes Dev. 21:537-551(2007).
[13]
INTERACTION WITH HUWE1.
PubMed=18488021; DOI=10.1038/ncb1727;
Zhao X., Heng J.I.-T., Guardavaccaro D., Jiang R., Pagano M.,
Guillemot F., Iavarone A., Lasorella A.;
"The HECT-domain ubiquitin ligase Huwe1 controls neural
differentiation and proliferation by destabilizing the N-Myc
oncoprotein.";
Nat. Cell Biol. 10:643-653(2008).
[14]
FUNCTION, TISSUE SPECIFICITY, INTERACTION WITH NCYM, AND
PHOSPHORYLATION.
PubMed=24391509; DOI=10.1371/journal.pgen.1003996;
Suenaga Y., Islam S.M., Alagu J., Kaneko Y., Kato M., Tanaka Y.,
Kawana H., Hossain S., Matsumoto D., Yamamoto M., Shoji W., Itami M.,
Shibata T., Nakamura Y., Ohira M., Haraguchi S., Takatori A.,
Nakagawara A.;
"NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein
that inhibits GSK3beta resulting in the stabilization of MYCN in human
neuroblastomas.";
PLoS Genet. 10:E1003996-E1003996(2014).
[15] {ECO:0000244|PDB:5G1X}
X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 28-89 IN COMPLEX WITH AURKA,
INTERACTION WITH AURKA AND FBXW7, MUTAGENESIS OF PHE-28; TYR-29;
PHE-35; TYR-36; 52-LYS--LEU-56; GLU-73; TRP-77 AND TRP-88, REGION, AND
PHOSPHORYLATION.
PubMed=27837025; DOI=10.1073/PNAS.1610626113;
Richards M.W., Burgess S.G., Poon E., Carstensen A., Eilers M.,
Chesler L., Bayliss R.;
"Structural basis of N-Myc binding by Aurora-A and its destabilization
by kinase inhibitors.";
Proc. Natl. Acad. Sci. U.S.A. 113:13726-13731(2016).
[16]
VARIANTS FGLDS1 HIS-393; SER-393 AND HIS-394.
PubMed=15821734; DOI=10.1038/ng1546;
van Bokhoven H., Celli J., van Reeuwijk J., Rinne T., Glaudemans B.,
van Beusekom E., Rieu P., Newbury-Ecob R.A., Chiang C., Brunner H.G.;
"MYCN haploinsufficiency is associated with reduced brain size and
intestinal atresias in Feingold syndrome.";
Nat. Genet. 37:465-467(2005).
[17]
INVOLVEMENT IN FGLDS1.
PubMed=16906565; DOI=10.1002/ajmg.a.31407;
Teszas A., Meijer R., Scheffer H., Gyuris P., Kosztolanyi G.,
van Bokhoven H., Kellermayer R.;
"Expanding the clinical spectrum of MYCN-related Feingold syndrome.";
Am. J. Med. Genet. A 140:2254-2256(2006).
-!- FUNCTION: Positively regulates the transcription of MYCNOS in
neuroblastoma cells. {ECO:0000269|PubMed:24391509}.
-!- SUBUNIT: Efficient DNA binding requires dimerization with another
bHLH protein. Binds DNA as a heterodimer with MAX. Interacts with
KDM5A, KDM5B and HUWE1. Interacts with MYCNOS. Interacts with
AURKA; interaction is phospho-independent and triggers AURKA
activation; AURKA competes with FBXW7 for binding to
unphosphorylated MYCN but not for binding to unphosphorylated MYCN
(PubMed:27837025). Interacts with FBXW7; FBXW7 competes with AURKA
for binding to unphosphorylated MYCN but not for binding to
phosphorylated MYCN (PubMed:27837025).
{ECO:0000269|PubMed:17311883, ECO:0000269|PubMed:18488021,
ECO:0000269|PubMed:24391509, ECO:0000269|PubMed:27837025}.
-!- INTERACTION:
O14965:AURKA; NbExp=12; IntAct=EBI-878369, EBI-448680;
P97477:Aurka (xeno); NbExp=2; IntAct=EBI-878369, EBI-6895349;
Q8N726:CDKN2A; NbExp=3; IntAct=EBI-878369, EBI-625922;
P61244:MAX; NbExp=10; IntAct=EBI-878369, EBI-751711;
Q13287:NMI; NbExp=3; IntAct=EBI-878369, EBI-372942;
Q96EB6:SIRT1; NbExp=3; IntAct=EBI-878369, EBI-1802965;
Q13105:ZBTB17; NbExp=3; IntAct=EBI-878369, EBI-372156;
-!- SUBCELLULAR LOCATION: Nucleus.
-!- TISSUE SPECIFICITY: Expressed in the neuronal cells of the
cerebrum, neuroblastomas and thyroid tumors (at protein level).
{ECO:0000269|PubMed:24391509}.
-!- DEVELOPMENTAL STAGE: Expressed during fetal development.
-!- PTM: Phosphorylated by GSK3-beta which may promote its degradation
(PubMed:24391509). Phosphorylated by AURKA (PubMed:27837025).
{ECO:0000269|PubMed:24391509, ECO:0000269|PubMed:27837025}.
-!- DISEASE: Note=Amplification of the N-MYC gene is associated with a
variety of human tumors, most frequently neuroblastoma, where the
level of amplification appears to increase as the tumor
progresses. {ECO:0000269|PubMed:2834684}.
-!- DISEASE: Feingold syndrome 1 (FGLDS1) [MIM:164280]: A syndrome
characterized by variable combinations of esophageal and duodenal
atresias, microcephaly, learning disability, mental retardation,
and limb malformations. Hand and foot abnormalities may include
hypoplastic thumbs, clinodactyly of second and fifth fingers,
syndactyly (characteristically between second and third and fourth
and fifth toes), and shortened or absent middle phalanges. Cardiac
and renal malformations, vertebral anomalies, and deafness have
also been described. {ECO:0000269|PubMed:15821734,
ECO:0000269|PubMed:16906565}. Note=The disease is caused by
mutations affecting the gene represented in this entry.
-!- SEQUENCE CAUTION:
Sequence=AAA36371.1; Type=Erroneous initiation; Evidence={ECO:0000305};
Sequence=CAA68678.1; Type=Erroneous initiation; Evidence={ECO:0000305};
-!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
and Haematology;
URL="http://atlasgeneticsoncology.org/Genes/NMYCID112.html";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; X03294; CAA27037.1; -; Genomic_DNA.
EMBL; X03295; CAA27038.1; -; Genomic_DNA.
EMBL; M13241; AAA36371.1; ALT_INIT; Genomic_DNA.
EMBL; M13228; AAA36370.1; -; Genomic_DNA.
EMBL; BT007384; AAP36048.1; -; mRNA.
EMBL; AC010145; AAY14952.1; -; Genomic_DNA.
EMBL; CH471053; EAX00885.1; -; Genomic_DNA.
EMBL; CH471053; EAX00886.1; -; Genomic_DNA.
EMBL; CH471053; EAX00887.1; -; Genomic_DNA.
EMBL; CH471053; EAX00888.1; -; Genomic_DNA.
EMBL; BC002712; AAH02712.1; -; mRNA.
EMBL; M18090; AAA59885.1; -; Genomic_DNA.
EMBL; X02363; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; Y00664; CAA68678.1; ALT_INIT; Genomic_DNA.
CCDS; CCDS1687.1; -.
PIR; A01355; TVHUMC.
PIR; A25744; TVHUM2.
RefSeq; NP_001280157.1; NM_001293228.1.
RefSeq; NP_001280160.1; NM_001293231.1.
RefSeq; NP_001280162.1; NM_001293233.1.
RefSeq; NP_005369.2; NM_005378.5.
RefSeq; XP_016859657.1; XM_017004168.1.
UniGene; Hs.25960; -.
PDB; 5G1X; X-ray; 1.72 A; B=28-89.
PDBsum; 5G1X; -.
ProteinModelPortal; P04198; -.
SMR; P04198; -.
BioGrid; 110698; 21.
DIP; DIP-36822N; -.
IntAct; P04198; 17.
MINT; MINT-1671085; -.
STRING; 9606.ENSP00000281043; -.
iPTMnet; P04198; -.
PhosphoSitePlus; P04198; -.
BioMuta; MYCN; -.
DMDM; 127604; -.
EPD; P04198; -.
PaxDb; P04198; -.
PeptideAtlas; P04198; -.
PRIDE; P04198; -.
DNASU; 4613; -.
Ensembl; ENST00000281043; ENSP00000281043; ENSG00000134323.
GeneID; 4613; -.
KEGG; hsa:4613; -.
UCSC; uc002rci.4; human.
CTD; 4613; -.
DisGeNET; 4613; -.
EuPathDB; HostDB:ENSG00000134323.10; -.
GeneCards; MYCN; -.
GeneReviews; MYCN; -.
H-InvDB; HIX0117705; -.
HGNC; HGNC:7559; MYCN.
HPA; HPA057420; -.
MalaCards; MYCN; -.
MIM; 164280; phenotype.
MIM; 164840; gene.
neXtProt; NX_P04198; -.
OpenTargets; ENSG00000134323; -.
Orphanet; 391641; Feingold syndrome type 1.
Orphanet; 635; Neuroblastoma.
Orphanet; 357034; Unilateral retinoblastoma.
PharmGKB; PA31359; -.
eggNOG; ENOG410IJ8V; Eukaryota.
eggNOG; ENOG41105VW; LUCA.
GeneTree; ENSGT00510000046414; -.
HOGENOM; HOG000043075; -.
HOVERGEN; HBG000472; -.
InParanoid; P04198; -.
KO; K09109; -.
OMA; FAEHSSE; -.
OrthoDB; EOG091G0ZJQ; -.
PhylomeDB; P04198; -.
TreeFam; TF106001; -.
SignaLink; P04198; -.
SIGNOR; P04198; -.
ChiTaRS; MYCN; human.
GeneWiki; N-Myc; -.
GenomeRNAi; 4613; -.
PRO; PR:P04198; -.
Proteomes; UP000005640; Chromosome 2.
Bgee; ENSG00000134323; -.
CleanEx; HS_MYCN; -.
Genevisible; P04198; HS.
GO; GO:0000785; C:chromatin; TAS:ProtInc.
GO; GO:0005730; C:nucleolus; IDA:HPA.
GO; GO:0005634; C:nucleus; IDA:UniProtKB.
GO; GO:0003677; F:DNA binding; TAS:UniProtKB.
GO; GO:0019900; F:kinase binding; IPI:UniProtKB.
GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
GO; GO:0000978; F:RNA polymerase II core promoter proximal region sequence-specific DNA binding; IDA:NTNU_SB.
GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; TAS:ProtInc.
GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding; IDA:NTNU_SB.
GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
GO; GO:0001502; P:cartilage condensation; IEA:Ensembl.
GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
GO; GO:0048704; P:embryonic skeletal system morphogenesis; IEA:Ensembl.
GO; GO:0030324; P:lung development; IEA:Ensembl.
GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl.
GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IEA:Ensembl.
GO; GO:0010942; P:positive regulation of cell death; IEA:Ensembl.
GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL.
GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
GO; GO:1903800; P:positive regulation of production of miRNAs involved in gene silencing by miRNA; IC:BHF-UCL.
GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:NTNU_SB.
GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
GO; GO:0045607; P:regulation of auditory receptor cell differentiation; IEA:Ensembl.
GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:BHF-UCL.
CDD; cd00083; HLH; 1.
Gene3D; 4.10.280.10; -; 1.
InterPro; IPR011598; bHLH_dom.
InterPro; IPR036638; HLH_DNA-bd_sf.
InterPro; IPR002418; Tscrpt_reg_Myc.
InterPro; IPR012682; Tscrpt_reg_Myc_N.
Pfam; PF00010; HLH; 1.
Pfam; PF01056; Myc_N; 1.
PIRSF; PIRSF001705; Myc_protein; 1.
PRINTS; PR00044; LEUZIPPRMYC.
SMART; SM00353; HLH; 1.
SUPFAM; SSF47459; SSF47459; 1.
PROSITE; PS50888; BHLH; 1.
1: Evidence at protein level;
3D-structure; Activator; Complete proteome; Disease mutation;
DNA-binding; Nucleus; Phosphoprotein; Proto-oncogene;
Reference proteome; Transcription; Transcription regulation.
CHAIN 1 464 N-myc proto-oncogene protein.
/FTId=PRO_0000127323.
DOMAIN 381 433 bHLH. {ECO:0000255|PROSITE-
ProRule:PRU00981}.
REGION 19 47 Interaction with AURKA.
{ECO:0000269|PubMed:27837025}.
REGION 61 89 Interaction with AURKA and FBXW7.
{ECO:0000269|PubMed:27837025}.
REGION 433 454 Leucine-zipper.
COMPBIAS 262 278 Asp/Glu-rich (acidic).
MOD_RES 261 261 Phosphoserine; by CK2.
{ECO:0000269|PubMed:1425701}.
MOD_RES 263 263 Phosphoserine; by CK2.
{ECO:0000269|PubMed:1425701}.
VARIANT 393 393 R -> H (in FGLDS1; dbSNP:rs104893646).
{ECO:0000269|PubMed:15821734}.
/FTId=VAR_031952.
VARIANT 393 393 R -> S (in FGLDS1; dbSNP:rs104893647).
{ECO:0000269|PubMed:15821734}.
/FTId=VAR_031953.
VARIANT 394 394 R -> H (in FGLDS1; dbSNP:rs104893648).
{ECO:0000269|PubMed:15821734}.
/FTId=VAR_031954.
MUTAGEN 28 28 F->A: Reduces interaction with AURKA;
when associated with A-35.
{ECO:0000269|PubMed:27837025}.
MUTAGEN 29 29 Y->A: Reduces interaction with AURKA;
when associated with A-36.
{ECO:0000269|PubMed:27837025}.
MUTAGEN 35 35 F->A: Reduces interaction with AURKA;
when associated with A-28.
{ECO:0000269|PubMed:27837025}.
MUTAGEN 36 36 Y->A: Reduces interaction with AURKA;
when associated with A-29.
{ECO:0000269|PubMed:27837025}.
MUTAGEN 52 56 KFELL->AAAAA: Does not affect AURKA
binding. {ECO:0000269|PubMed:27837025}.
MUTAGEN 73 73 E->K: Reduces binding to AURKA.
{ECO:0000269|PubMed:27837025}.
MUTAGEN 77 77 W->A: Reduces binding to AURKA.
{ECO:0000269|PubMed:27837025}.
MUTAGEN 88 88 W->A: Abrogates the interaction with
AURKA. {ECO:0000269|PubMed:27837025}.
CONFLICT 227 227 A -> P (in Ref. 2; CAA27037).
{ECO:0000305}.
CONFLICT 363 363 I -> V (in Ref. 3; CAA68678).
{ECO:0000305}.
HELIX 69 71 {ECO:0000244|PDB:5G1X}.
HELIX 76 88 {ECO:0000244|PDB:5G1X}.
SEQUENCE 464 AA; 49561 MW; 560E885602E30DAD CRC64;
MPSCSTSTMP GMICKNPDLE FDSLQPCFYP DEDDFYFGGP DSTPPGEDIW KKFELLPTPP
LSPSRGFAEH SSEPPSWVTE MLLENELWGS PAEEDAFGLG GLGGLTPNPV ILQDCMWSGF
SAREKLERAV SEKLQHGRGP PTAGSTAQSP GAGAASPAGR GHGGAAGAGR AGAALPAELA
HPAAECVDPA VVFPFPVNKR EPAPVPAAPA SAPAAGPAVA SGAGIAAPAG APGVAPPRPG
GRQTSGGDHK ALSTSGEDTL SDSDDEDDEE EDEEEEIDVV TVEKRRSSSN TKAVTTFTIT
VRPKNAALGP GRAQSSELIL KRCLPIHQQH NYAAPSPYVE SEDAPPQKKI KSEASPRPLK
SVIPPKAKSL SPRNSDSEDS ERRRNHNILE RQRRNDLRSS FLTLRDHVPE LVKNEKAAKV
VILKKATEYV HSLQAEEHQL LLEKEKLQAR QQQLLKKIEH ARTC


Related products :

Catalog number Product name Quantity
EIAAB25932 bHLHe37,BHLHE37,Class E basic helix-loop-helix protein 37,Homo sapiens,Human,MYCN,NMYC,N-myc proto-oncogene protein
EIAAB37697 Basic helix-loop-helix transcription factor scleraxis,bHLHa41,BHLHA41,bHLHa48,Class A basic helix-loop-helix protein 41,Class A basic helix-loop-helix protein 48,Homo sapiens,Human,SCX,SCXA
E1290h ELISA bHLHe39,BHLHE39,Class E basic helix-loop-helix protein 39,Homo sapiens,Human,MYC,Myc proto-oncogene protein,Proto-oncogene c-Myc,Transcription factor p64 96T
E1290h ELISA kit bHLHe39,BHLHE39,Class E basic helix-loop-helix protein 39,Homo sapiens,Human,MYC,Myc proto-oncogene protein,Proto-oncogene c-Myc,Transcription factor p64 96T
U1290h CLIA bHLHe39,BHLHE39,Class E basic helix-loop-helix protein 39,Homo sapiens,Human,MYC,Myc proto-oncogene protein,Proto-oncogene c-Myc,Transcription factor p64 96T
U2004h CLIA Basic-helix-loop-helix-PAS protein MOP2,bHLHe73,BHLHE73,Class E basic helix-loop-helix protein 73,Endothelial PAS domain-containing protein 1,EPAS1,EPAS-1,HIF-1-alpha-like factor,HIF2A,HIF-2-alph 96T
E2004h ELISA kit Basic-helix-loop-helix-PAS protein MOP2,bHLHe73,BHLHE73,Class E basic helix-loop-helix protein 73,Endothelial PAS domain-containing protein 1,EPAS1,EPAS-1,HIF-1-alpha-like factor,HIF2A,HIF- 96T
U2004h CLIA kit Basic-helix-loop-helix-PAS protein MOP2,bHLHe73,BHLHE73,Class E basic helix-loop-helix protein 73,Endothelial PAS domain-containing protein 1,EPAS1,EPAS-1,HIF-1-alpha-like factor,HIF2A,HIF-2 96T
E2004h ELISA Basic-helix-loop-helix-PAS protein MOP2,bHLHe73,BHLHE73,Class E basic helix-loop-helix protein 73,Endothelial PAS domain-containing protein 1,EPAS1,EPAS-1,HIF-1-alpha-like factor,HIF2A,HIF-2-alp 96T
EIAAB28826 bHLHb1,BHLHB1,bHLHe19,BHLHE19,Class B basic helix-loop-helix protein 1,Class E basic helix-loop-helix protein 19,Homo sapiens,Human,OLIG2,Oligo2,Oligodendrocyte transcription factor 2,PRKCBP2,Protein
EIAAB28821 bHLHb6,BHLHB6,bHLHe21,BHLHE21,Class B basic helix-loop-helix protein 6,Class E basic helix-loop-helix protein 21,Homo sapiens,Human,OLIG1,Oligo1,Oligodendrocyte transcription factor 1
EIAAB28828 bHLHb7,BHLHB7,bHLHe20,BHLHE20,Class B basic helix-loop-helix protein 7,Class E basic helix-loop-helix protein 20,Homo sapiens,Human,OLIG3,Oligo3,Oligodendrocyte transcription factor 3
U0798h CLIA ARNT-interacting protein,Basic-helix-loop-helix-PAS protein MOP1,bHLHe78,BHLHE78,Class E basic helix-loop-helix protein 78,HIF1A,HIF-1-alpha,HIF1-alpha,Homo sapiens,Human,Hypoxia-inducible factor 96T
E0798h ELISA ARNT-interacting protein,Basic-helix-loop-helix-PAS protein MOP1,bHLHe78,BHLHE78,Class E basic helix-loop-helix protein 78,HIF1A,HIF-1-alpha,HIF1-alpha,Homo sapiens,Human,Hypoxia-inducible facto 96T
E0798h ELISA kit ARNT-interacting protein,Basic-helix-loop-helix-PAS protein MOP1,bHLHe78,BHLHE78,Class E basic helix-loop-helix protein 78,HIF1A,HIF-1-alpha,HIF1-alpha,Homo sapiens,Human,Hypoxia-inducible 96T
E0255h ELISA kit ATH1,ATOH1,bHLHa14,BHLHA14,Class A basic helix-loop-helix protein 14,hATH1,Helix-loop-helix protein hATH-1,Homo sapiens,Human,Protein atonal homolog 1 96T
U0255h CLIA ATH1,ATOH1,bHLHa14,BHLHA14,Class A basic helix-loop-helix protein 14,hATH1,Helix-loop-helix protein hATH-1,Homo sapiens,Human,Protein atonal homolog 1 96T
E0255h ELISA ATH1,ATOH1,bHLHa14,BHLHA14,Class A basic helix-loop-helix protein 14,hATH1,Helix-loop-helix protein hATH-1,Homo sapiens,Human,Protein atonal homolog 1 96T
EIAAB14718 Basic helix-loop-helix protein N-twist,bHLHa31,BHLHA31,Class A basic helix-loop-helix protein 31,Fer3-like protein,FERD3L,Homo sapiens,Human,NATO3,Nephew of atonal 3,Neuronal twist,NTWIST
EIAAB27132 bHLHa6,BHLHA6,Class A basic helix-loop-helix protein 6,Homo sapiens,Human,NeuroD3,NEUROD3,NEUROG1,Neurogenic basic-helix-loop-helix protein,Neurogenic differentiation factor 3,Neurogenin-1,NGN,NGN1,NG
EIAAB27612 Basic-helix-loop-helix-PAS protein MOP5,bHLHe11,BHLHE11,Class E basic helix-loop-helix protein 11,Homo sapiens,Human,Member of PAS protein 5,MOP5,Neuronal PAS domain-containing protein 1,Neuronal PAS1
EIAAB27615 Basic-helix-loop-helix-PAS protein MOP4,bHLHe9,BHLHE9,Class E basic helix-loop-helix protein 9,Homo sapiens,Human,Member of PAS protein 4,MOP4,Neuronal PAS domain-containing protein 2,Neuronal PAS2,NP
EIAAB27618 Basic-helix-loop-helix-PAS protein MOP6,bHLHe12,BHLHE12,Class E basic helix-loop-helix protein 12,Homo sapiens,Human,Member of PAS protein 6,MOP6,Neuronal PAS domain-containing protein 3,Neuronal PAS3
LF-PA40832 anti-Basic-helix-loop-helix-PAS Protein, Rabbit polyclonal to Basic-helix-loop-helix-PAS Protein, Isotype IgG, Host Rabbit 50 ug
31-158 The tal-1 proto-oncogene encodes a helix-loop-helix DNA-binding protein that has been implicated in the formation of T cell acute lymphoblastic leukemia (T-ALL). 0.1 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur